1-3 of 3
Alessio Fiascarelli
Close
Sort by
Journal Articles

Tagraxofusp Shows Promising Anti-Tumoral Efficacy in Preclinical in Vitro Models of Myelofibrosis, Both As a Single Agent and in Combination with Janus Kinase Inhibitors

Maria Luisa Iannitto, Diego Bisignano, Alessio Fiascarelli, Simone Talucci, Sonia Zicari, Francesco Belli, Alessandro Bressan, Christopher Brooks, Daniela Bellarosa, Monica Binaschi
Journal: Blood
Blood (2023) 142 (Supplement 1): 6329.
https://doi.org/10.1182/blood-2023-178864
Published: 2023
Journal Articles

PIM Inhibition By SEL24/MEN1703 Combines Synergistically with Gilteritinib in FLT3-ITD Preclinical Models of Acute Myeloid Leukemia

Daniela Bellarosa, Sonia Zicari, Giuseppe Merlino, Alessio Fiascarelli, Diego Bisignano, Francesco Belli, Clelia Irrissuto, Simone Talucci, Maria Luisa Iannitto, Mario Bigioni, Alessandro Bressan, Krzysztof Brzózka, Gabriel Ghiaur, Monica Binaschi
Journal: Blood
Blood (2022) 140 (Supplement 1): 3090–3091.
https://doi.org/10.1182/blood-2022-168491
Published: 2022
Journal Articles

Identification of a Pharmacodynamic Biomarker for SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor for Acute Myeloid Leukemia, and Its Implementation in the First-in-Human Study CLI24-001

Andrea Tomirotti, PhD, Giuseppe Merlino, Alessio Fiascarelli, PhD, Simone Baldini, MD, Alessia Tagliavini, Elisa Borella, Milena Mazan, PhD, Krzysztof Brzózka, PhD, Alessandro Bressan, Andrea Pellacani, PhD MD, Massimiliano Salerno, Monica Binaschi, PhD, Daniela Bellarosa
Journal: Blood
Blood (2019) 134 (Supplement_1): 5087.
https://doi.org/10.1182/blood-2019-124800
Published: 2019